Our Technology

CY-101 selectively targets and disrupts cancer cell membranes. This releases tumor neoantigens to the immune system, allowing it to mount a systemic, cancer-specific, immune response. Moreover, CY-101 inhibits the β-catenin pathway, disrupting tumor growth and further stimulating the immune system.

Our
Technology

CY-101 selectively targets and disrupts cancer cell membranes. This releases tumor neoantigens to the immune system, allowing it to mount a systemic, cancer-specific, immune response. Moreover, CY-101 inhibits the β-catenin pathway, disrupting tumor growth and further stimulating the immune system.

CY-101 is a stable peptide with a dual mode of action that selectively targets cancer cells